Precigen (NASDAQ:PGEN) Upgraded to “Strong-Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Precigen (NASDAQ:PGEN) from a hold rating to a strong-buy rating in a report published on Saturday morning.

A number of other analysts have also commented on the stock. Citigroup reiterated an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. HC Wainwright raised their target price on shares of Precigen from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday. Citizens Jmp raised their target price on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a research report on Friday, July 17th. Finally, Zacks Research upgraded shares of Precigen from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $14.50.

Precigen Trading Up 4.6%

Precigen stock opened at $7.23 on Friday. Precigen has a one year low of $1.70 and a one year high of $7.26. The business’s fifty day moving average is $5.23 and its 200 day moving average is $4.50. The stock has a market capitalization of $2.58 billion, a PE ratio of -6.95 and a beta of 1.02. The company has a debt-to-equity ratio of 2.15, a current ratio of 4.58 and a quick ratio of 4.12.

Precigen (NASDAQ:PGEN) last issued its earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. The business had revenue of $54.98 million during the quarter, compared to analyst estimates of $27.98 million. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The business’s revenue for the quarter was up 6322.7% on a year-over-year basis. On average, sell-side analysts predict that Precigen will post 0.05 EPS for the current year.

Insider Buying and Selling at Precigen

In other news, COO Rutul R. Shah sold 32,739 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $6.86, for a total value of $224,589.54. Following the transaction, the chief operating officer owned 465,012 shares in the company, valued at $3,189,982.32. This represents a 6.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Donald P. Lehr sold 29,131 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $4.36, for a total transaction of $127,011.16. Following the completion of the transaction, the insider directly owned 755,461 shares in the company, valued at approximately $3,293,809.96. The trade was a 3.71% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 989,239 shares of company stock worth $5,472,960 over the last 90 days. 41.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Occam Crest Management LP increased its stake in shares of Precigen by 29.6% in the 4th quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock worth $14,637,000 after purchasing an additional 799,339 shares in the last quarter. KBC Group NV purchased a new position in Precigen during the first quarter valued at $1,338,000. UBS Group AG lifted its position in Precigen by 41.4% during the fourth quarter. UBS Group AG now owns 891,428 shares of the biotechnology company’s stock valued at $3,726,000 after purchasing an additional 260,824 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in Precigen during the first quarter valued at about $1,531,000. Finally, Investment Insight Wealth Management LLC bought a new stake in Precigen during the fourth quarter valued at about $443,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Key Headlines Impacting Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong earnings and commercial momentum: Precigen reported second-quarter 2026 revenue of approximately $55 million, far exceeding analyst expectations, and earnings of $0.05 per share versus the expected $0.01 loss. Revenue was driven largely by PAPZIMEOS, whose sales reportedly doubled sequentially to $53.1 million. The company also achieved quarterly profitability, supporting the view that its commercial business is scaling rapidly. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: More favorable analyst outlook: HC Wainwright maintained a Buy rating and an $18 price target while raising its Q3 2026 EPS forecast to $0.05 from $0.01 and its full-year 2026 forecast to $0.14 from $0.02. The firm also lifted its FY2027 estimate to $0.44 from $0.34, reflecting expectations for continued profitability and growth. HC Wainwright Precigen Estimates
• Positive Sentiment: Additional bullish ratings: Zacks Research upgraded Precigen from “Hold” to “Strong Buy.” Separately, an investment analysis cited PAPZIMEOS’ FDA approval for recurrent respiratory papillomatosis, seven years of U.S. market exclusivity, possible European approval, and advancement of the PRGN-2009 program as potential drivers of future revenue. Zacks Research
• Neutral Sentiment: HC Wainwright’s projections imply a sharp earnings ramp, reaching $0.71 EPS in FY2028 and $1.49 EPS in FY2030. However, the firm made a small reduction to its FY2028 estimate, from $0.72 to $0.71, indicating that longer-term forecasts remain subject to execution risk.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.